{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:00:01Z","timestamp":1777464001055,"version":"3.51.4"},"reference-count":31,"publisher":"Wiley","issue":"19","license":[{"start":{"date-parts":[[2012,3,5]],"date-time":"2012-03-05T00:00:00Z","timestamp":1330905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Burkitt lymphoma post\u2010transplantation lymphoproliferative disorder (Burkitt\u2010PTLD) is a rare form of monomorphic B\u2010cell PTLD for which no standard treatment has been established. Currently, the treatment of Burkitt lymphoma outside the post\u2010transplantation setting involves high doses of alkylating agents, frequent dosing, and intrathecal and\/or systemic central nervous system prophylaxis. In PTLD, however, such protocols are associated with considerable toxicity and mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>The authors present a retrospective series of 8 adult patients with Burkitt\u2010PTLD. Six patients were reported to the prospective German PTLD registry or were enrolled in the PTLD\u20101 trial, and 2 patients had received treatment before 2000, thus allowing for comparison with the pre\u2010rituximab era.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Seven of the 8 patients were men. The median age at presentation was 38 years, and the median time since transplantation was 5.7 years. Five of 8 patients had histologically established, Epstein\u2010Barr virus\u2010associated disease, and 7 of 7 patients were positive for a <jats:italic>MYC<\/jats:italic> translocation. Five of 8 patients received sequential immunochemotherapy (4 courses of rituximab [R] followed by 4 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisolone [CHOP] or R plus CHOP [R\u2010CHOP]). In this group, 5 of 5 patients reached complete remission (CR), and their overall survival (OS) was significantly longer (<jats:italic>P<\/jats:italic> = .008) compared with the OS for 2 of 8 patients who received first\u2010line CHOP and did not respond. One of 8 patients (who had stage IV disease with meningiosis) received combination therapy (cyclophosphamide pretreatment, rituximab, intrathecal chemotherapy, whole\u2010brain irradiation, and radioimmunotherapy) and reached CR. Overall, 6 of 8 patients reached CR; and, after a median follow\u2010up of 4.7 years (range, 1.7\u20104.8 years), the median OS was 36.7 months. There was no treatment\u2010related mortality under first\u2010line therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>In the largest adult case series in Burkitt\u2010PTLD to date, sequential immunochemotherapy with rituximab followed by standard CHOP or R\u2010CHOP was a both safe and effective treatment. Cancer 2012. \u00a9 2012 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.27482","type":"journal-article","created":{"date-parts":[[2012,3,5]],"date-time":"2012-03-05T20:08:37Z","timestamp":1330978117000},"page":"4715-4724","source":"Crossref","is-referenced-by-count":35,"title":["Burkitt post\u2010transplantation lymphoma in adult solid organ transplant recipients"],"prefix":"10.1002","volume":"118","author":[{"given":"Heiner","family":"Zimmermann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Reinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Neuhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Lehmkuhl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Oertel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Atta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Planker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"G\u00e4rtner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dido","family":"Lenze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Anagnostopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanno","family":"Riess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf U.","family":"Trappe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,3,5]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.18004619704"},{"key":"e_1_2_6_3_2","first-page":"262","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Leoncini L","year":"2008"},{"key":"e_1_2_6_4_2","first-page":"106","article-title":"Malignant lymphomas in transplantation patients","volume":"1","author":"Penn I","year":"1969","journal-title":"Transplant Proc."},{"key":"e_1_2_6_5_2","first-page":"343","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01098.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0377"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70300-X"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(64)91524-7"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210240"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08159.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3947"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2008.1.341"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600685467"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23522"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.060"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq677"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21776"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10595"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190309178777"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200306000-00014"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26001"},{"key":"e_1_2_6_23_2","first-page":"114","article-title":"Sequential treatment with rituximab and CHOP chemotherapy in B\u2010cell PTLD\u2014moving forward to a first standard of care: results from a prospective international multicenter trial [abstract]","author":"Trappe R","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)."},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04705.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.039214"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318242162d"},{"key":"e_1_2_6_27_2","first-page":"1267","article-title":"Relapse patterns in Burkitt's lymphoma","volume":"32","author":"Ziegler JL","year":"1972","journal-title":"Cancer Res."},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh262"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.6.847"},{"key":"e_1_2_6_30_2","first-page":"108","article-title":"Novel Treatment of Burkitt lymphoma with dose\u2010adjusted EPOCH\u2010rituximab: preliminary results showing excellent outcome [abstract]","author":"Dunleavy K","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)."},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.8.2685"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03387.x"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.27482","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.27482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T23:59:35Z","timestamp":1760313575000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.27482"}},"subtitle":["Sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R\u2010CHOP is safe and effective in an analysis of 8 patients"],"short-title":[],"issued":{"date-parts":[[2012,3,5]]},"references-count":31,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1002\/cncr.27482"],"URL":"https:\/\/doi.org\/10.1002\/cncr.27482","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,5]]}}}